Introduction: From research and development to market launch, innovative drugs require a long cycle and significant investment, and their commercial value heavily depends on intellectual property
Introduction On August 5, the China Intellectual Property Research Association, together with 13 overseas guiding council member units including the Commercial Legal Service Center of the
This week, financing news in the biopharmaceutical sector has arrived: eight innovative companies, including Huode Biotech, Deep Cell, and Zhongke Aoge, have successively secured financing ranging
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to China Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into credible
· National Intellectual Property Administration's Party Group Theoretically Studies Xi Jinping's Party Building Thought · Adjustment of PCT Application International Phase Fees from August 1, 2026
Measures for the Administration of Patent Priority Examination Chapter 1 General Provisions Article 1 In order to further advance the construction of a strong intellectual property nation
A tiny injection pen cap has unexpectedly become the fuse for the “battle of the gods” in the domestic GLP-1 sector. On July 10, Yinnuo Pharma
Medical devices are a crucial pillar of the biopharmaceutical industry and one of the most intensive tracks for technology transfer. Unlike innovative drugs, which often have
On July 29, the National Medical Products Administration approved four innovative drugs at once, covering autoimmunity, metabolite,Anti-infectionand the four major fields of traditional Chinese medicine! 1.Huahai
· State Intellectual Property Office: China's Trademark Legislation Upgrades from "Partial Revision" to "Systematic Improvement" · Canada-China Patent Prosecution Highway (PPH) Pilot Project Extended · China-EU